Literature DB >> 27434288

Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma.

Jia-Zhu Wu, Tian Tian, Ying Huang, Jin-Hua Liang, Yi Miao, Li Wang, Ji Xu, Xiao-Yan Qu, Lei Fan, Jian-Yong Li, Wei Xu.   

Abstract

BACKGROUND: Carbohydrate antigen 125 (CA-125) is one of the most common used tumor biomarkers in clinical practice. Previous studies showed an association of increased CA-125 levels with advanced characteristics and inferior outcome in non-Hodgkin lymphoma.
OBJECTIVE: To identify the clinical significance of CA-125 in diffuse large B-cell lymphoma (DLBCL).
METHODS: We retrospectively analyzed 181 patients with DLBCL with measured serum CA-125 concentration at diagnosis and follow-ups during the courses. Clinical significance of CA-125 was evaluated by assessing the association between CA-125 levels and clinical characteristics.
RESULTS: CA-125 levels on admission were positively correlated with serum lactate dehydrogenase, β2-microglobulin (β2-MG), serum ferritin (SF) and cavity effusion, while negatively correlated with serum albumen (ALB). During the courses, CA-125 levels were positively correlated with β 2-MG, SF and effusion, and negatively correlated with ALB. A better correlation between effusion and CA-125 levels was observed. Using a cut-off value > 50.39 U/ml gave a sensitivity of 73.8% and a specificity of 92.1% for the indication of effusion at diagnosis, while during the courses the sensitivity was much lower. On the prognostic role of CA-125, we found prognostic relevance on progression-free survival (PFS) but not on overall survival (OS).
CONCLUSIONS: Our study revealed limited usefulness of CA-125 concentration at diagnosis and follow-ups in DLBCL.

Entities:  

Keywords:  CA-125; diffuse large B-cell lymphoma; prognosis; serosal effusion

Mesh:

Substances:

Year:  2016        PMID: 27434288     DOI: 10.3233/CBM-160632

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  2 in total

1.  Genetic heterogeneity and mutational signature in Chinese Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Authors:  Fang Liu; Zhe Wang; Xiaoge Zhou; Qing Liu; Gang Chen; Hualiang Xiao; Weihua Yin; Shigeo Nakamura; Huilan Rao
Journal:  PLoS One       Date:  2018-08-14       Impact factor: 3.240

2.  Rapid identification of novel independent serum biomarkers in diffuse large B-cell lymphoma.

Authors:  Yi-Qun Che; Di Wang; Peng Liu; Yue Zhang; Yang Luo; Hui-Ying Liu; Di Shen; Wei Cui
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.